Trevi Therapeutics price target raised to $20 from $12 at Oppenheimer
Oppenheimer raised the firm’s price target on Trevi Therapeutics (TRVI) to $20 from $12 and keeps an Outperform rating on the shares. The firm ...
Trevi Therapeutics (NASDAQ:TRVI) Stock Price Expected to Rise, Oppenheimer Analyst Says
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) had its price target increased by equities researchers at Oppenheimer from ...
Trevi Therapeutics meets main goal in chronic coughing treatment trial, stock surges
Trevi Therapeutics (NASDAQ:TRVI) stock jumped about 40% premarket after its mid-stage trial for Haduvio, a potential treatment for chronic coughing, met main goal. Haduvio, the company's ...
Trevi Therapeutics upgraded to Strong Buy from Outperform at Raymond James
Raymond James upgraded Trevi Therapeutics (TRVI) to Strong Buy from Outperform with a price target of $29, up from $9, after Haduvio delivered ...
Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps
Trevi's Haduvio met the primary endpoint in a Phase 2a trial, showing a significant reduction in cough frequency with no serious adverse events reported.
Trevi Therapeutics (NASDAQ:TRVI) Stock Price Expected to Rise, Needham & Company LLC Analyst Says
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) had its price target upped by equities research analysts at Needham & ...